Evidence map›Paper›PMID 40155432›Full record

Observational studyScientific reports2025

Role of soluble interleukin-2 receptor (sIL-2R) as a predictor for severe dengue infection.

Arkit Deep Singh, Atul Saroch, Ashok Kumar Pannu, Ashok Kumar Yadav, Saurabh C Sharda, Mandeep Bhatia, Kajal Kamboj

Abstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arkit Deep SinghDepartment of Internal Medicine, PGIMER Chandigarh, Room No.11, 4th Floor F Block Nehru Hospital, Chandigarh, India.
Atul SarochDepartment of Internal Medicine, PGIMER Chandigarh, Room No.11, 4th Floor F Block Nehru Hospital, Chandigarh, India. atulsaroch@gmail.com.
Ashok Kumar PannuDepartment of Internal Medicine, PGIMER Chandigarh, Room No.11, 4th Floor F Block Nehru Hospital, Chandigarh, India.
Ashok Kumar YadavDepartment of Experimental Medicine and Biotechnology, PGIMER Chandigarh, Chandigarh, India.
Saurabh C ShardaDepartment of Internal Medicine, PGIMER Chandigarh, Room No.11, 4th Floor F Block Nehru Hospital, Chandigarh, India.
Mandeep BhatiaDepartment of Internal Medicine, PGIMER Chandigarh, Room No.11, 4th Floor F Block Nehru Hospital, Chandigarh, India.
Kajal KambojDepartment of Experimental Medicine and Biotechnology, PGIMER Chandigarh, Chandigarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Annually, around half a million people with severe dengue require hospitalization, all over the globe, with around 12,500 (2.5%) succumbing to the illness. In this prospective observational study, we recruited 74 patients with dengue infection, 28 had severe dengue and 46 had dengue with warning signs. sIL-2R levels were significantly raised in the severe dengue group, compared to the warning signs group. Using an ROC curve (receive operator characteristic), at a cutoff of 5.379 ng/ml, it predicted the severe dengue classification with a p-value of < 0.001. As a marker for predicting hemophagocytic lymphohistiocytosis (HLH), the ROC curve revealed a cutoff of ≥ 5.379 ng/ml for sIL-2R levels with the AUROC being 0.83, suggesting a strong diagnostic performance(p-value < 0.001). sIL-2R levels can be used for predicting severe dengue classification with moderate sensitivity and specificity. Secondary HLH is an under-reported entity in dengue infection and early surveillance with the help of sIL-2R may be helpful in-patient care management.

Indexed as

DengueReceptors, Interleukin-2Severe DengueAdolescentAdultBiomarkersFemaleHumansLymphohistiocytosis, HemophagocyticMaleMiddle AgedProspective StudiesROC CurveSeverity of Illness IndexYoung AdultBiomarkersReceptors, Interleukin-2

Identifiers

PMID40155432
PMCPMC11953223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.